Aurobindo received FDA Approval for Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg
Published: August 11, 2020
East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg. Aurobindo’s Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg, are an AB-rated generic equivalent to the reference listed drug (RLD), ProAmatine Tablets 2.5 mg, 5 mg, and 10 mg, of Takeda Pharmaceuticals U.S.A., Inc.
Midodrine Hydrochloride Tablets are indicated for:
- The treatment of treatment of symptomatic orthostatic hypotension (OH)